\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe results of the evaluation are:
Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs - HORIZON-HLTH-2022-DISEASE-06-02-two-stage
Vaccines 2.0 - developing the next generation of vaccines - HORIZON-HLTH-2022-DISEASE-06-03-two-stage
Development of new effective therapies for rare diseases - HORIZON-HLTH-2022-DISEASE-06-04-two-stage
In accordance with General Annex D of the Work Programme, the evaluation of the first-stage proposals was made looking only at the criteria 'excellence' and 'impact'. The threshold for both individual criteria is 4. The overall threshold applying to the sum of the two individual scores was set at a level that ensures the total requested budget of proposals admitted to stage 2 is as close as possible to three times the available budget, and not less than two and a half times the available budget, and is as follows:
Source: Funding & Tenders Portal (Funding Updates)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
GenderSAFE, funded by Horizon Europe under call topic HORIZON-WIDERA-2023-ERA-01-09, is a project that advances efforts to implement a zero-tolerance approach to gender-based violence in higher education and research in the European Research Area. This overall objective will be achieved through a five-fold strategy. The project exists of a European-wide consortium of six partners. Read more about the GenderSAFE’s five-fold strategy, the role of the Belgian partner Yellow Window and the latest outputs of the project in this testimonial.
